|
|
||||||||
J. Biol. Chem., Vol. 275, Issue 27, 20762-20769, July 7, 2000
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
From the
Received for publication, February 23, 2000, and in revised form, April 11, 2000
GATA4 is a transcriptional activator of
cardiac-restricted promoters and is required for normal cardiac
morphogenesis. Friend of GATA-2 (FOG-2) is a multizinc finger protein
that associates with GATA4 and represses GATA4-dependent
transcription. To better understand the transcriptional repressor
activity of FOG-2 we performed a functional analysis of the FOG-2
protein. The results demonstrated that 1) zinc fingers 1 and 6 of FOG-2
are each capable of interacting with evolutionarily conserved motifs
within the N-terminal zinc finger of mammalian GATA proteins, 2) a
nuclear localization signal (RKRRK) (amino acids 736-740) is required to program nuclear targeting of FOG-2, and 3) FOG-2 can interact with
the transcriptional co-repressor, C-terminal-binding protein-2 via a
conserved sequence motif in FOG-2 (PIDLS). Surprisingly, however, this
interaction with C-terminal-binding protein-2 is not required for
FOG-2-mediated repression of GATA4-dependent transcription.
Instead, we have identified a novel N-terminal domain of FOG-2 (amino
acids 1-247) that is both necessary and sufficient to repress
GATA4-dependent transcription. This N-terminal repressor
domain is functionally conserved in the related protein, Friend of
GATA1. Taken together, these results define a set of evolutionarily
conserved mechanisms by which FOG proteins repress GATA-dependent transcription and thereby form the
foundation for genetic studies designed to elucidate the role of FOG-2
in cardiac development.
The GATA family of transcriptional activators contains six
mammalian members (GATA1-6) (1-7). Four of the mammalian GATA proteins are known to play critical roles in the development of the
hematopoeitic (GATA1-3) (8-10) and cardiovascular systems (GATA4) (1,
11-14). GATA4 is expressed at high levels in both embryonic and adult
cardiomyocytes and can bind to and activate the expression of multiple
cardiac-restricted promoters including those from the cTnC,
ANF, BNP, and myosin heavy chain (MHC)
genes (5, 15-17). GATA4-deficient mice produced by gene targeting die
at embryonic day 8.5 with severe defects in early cardiac morphogenesis
(18, 19).
All of the mammalian GATA proteins contain a DNA binding domain
composed of two evolutionarily conserved zinc fingers (N- and
C-terminal) and bind to the consensus DNA sequence WGATAR and its
variants (20, 21). Previous studies have demonstrated that several
transcription factors including erythroid Kruppel-like factor,
specificity protein 1, Nkx2.5, and nuclear factor of activated T cells
3 can associate specifically with the C-terminal zinc fingers of the
GATA proteins resulting in synergistic transcriptional activation (3,
22-25). The N-terminal zinc fingers of GATA proteins have also been
shown to mediate functionally important protein-protein interactions.
The structurally related zinc finger proteins U-shaped and Friend of
GATA1 (FOG)1 were both
identified by their ability to bind to the N-terminal zinc finger of
the GATA proteins Pannier and GATA1, respectively. Genetic studies
demonstrated that U-shaped represses the transcriptional activity of
the Drosophila GATA protein (26). FOG can function as either a
transcriptional co-activator or repressor of GATA1 depending on the
cell and promoter context being assayed (27-31).
We and others have recently identified a novel FOG family protein,
Friend of GATA-2 (FOG-2), that is structurally related to both FOG and
U-shaped (29, 32-34). FOG-2 is an 1151-amino acid polypeptide that
contains 8 zinc finger motifs and is expressed in the heart, brain, and
testis in adult mice. During mouse embryonic development, FOG-2 is
first expressed in the developing heart and septum transversum at
embryonic day 8.5. It is subsequently expressed in the urogenital
ridge, developing gut, and brain (33, 34). In each of these tissues its
pattern of expression overlaps with that of one or more GATA proteins.
FOG-2 specifically associates with the N-terminal zinc finger of GATA4
and represses GATA4-mediated transcriptional activation of several
cardiac-restricted promoters including those from the ANF, BNP, and
cTnC genes (33, 34).
In the studies described in this report, we have used in
vitro mutagenesis to functionally characterize the FOG-2 protein and to better understand the mechanisms by which it represses GATA4-dependent transcription from cardiac promoters. Our
results demonstrate that multiple zinc fingers of FOG-2 are capable of interacting with the N-terminal zinc finger of GATA4. Single amino acid
substitutions in conserved residues of the N-terminal zinc finger of
GATA4 can abolish FOG-2 binding and transcriptional repression without
disrupting the ability of GATA4 to bind to DNA or to activate
transcription. We have demonstrated that FOG-2 can physically associate
with a potent transcriptional co-repressor, C-terminal-binding
protein-2 (CtBP-2). However, this association is not required for FOG-2
to repress the GATA-mediated transcriptional activation of
cardiac-restricted promoters. Instead, we have identified a
non-CtBP-2-dependent repression domain of FOG-2 located at
the N terminus of the protein (aa 1 to 247). This domain is both
necessary and sufficient for FOG-2-mediated repression of
GATA4-dependent transcription and is functionally conserved
in the N-terminal region of FOG. Furthermore, when fused to a Gal4 DNA
binding domain, the N-terminal repressor domain of FOG-2 can repress
transcription from an SV40 promoter juxtaposed to Gal4 DNA binding
sites. Taken together, these results help to elucidate the molecular
mechanisms by which FOG-2 functions to repress
GATA4-dependent cardiac transcription and provide the
structural basis for ongoing studies designed to understand the
biochemical basis of FOG-2-mediated regulation of cardiomyocyte gene expression.
Plasmids--
PcDNA3-GATA4, pGEX-GATA4, and pcDNA3-FOG-2
have been described previously (33). pSV40Gal4luciferase containing
four copies of the Gal4 upstream activating sequence 5' of the SV40
promoter and the luciferase reporter gene was the generous gift of M. Lazar (University of Pennsylvania). PcDNA3-Nkx2.5 was
constructed by using the PCR and primers (5'-
GAGAATTCATGAATGGGGTGACGCAGAACTGC and 5'-CTGGGAAAGCAGGAGAGCACTTGG) to
generate a 521-bp fragment of the 5'-coding region of Nkx2.5, which was
then cloned into the EcoRI/XhoI sites of
pcDNA3. A 1-kb XhoI fragment from pBS-Csx was then
inserted into the XhoI site of this plasmid. Point mutations in the N-terminal zinc finger of GATA4 were created using PCR-directed mutagenesis with the following oligonucleotides:
5'-TTCCCGGGGACTACTGGGTCCCTG; 5'-GCTCTAGACCCAGACAAAGGGGCTGGCCAAGG; D2,
5'-CTGGAGGCGAGATGGGACGGAACACTACCTGTGCAATGCCTG; and D4,
5'-GGCCCCACAATTGACACACTTTCTGCCTTCTGAGAAGTCAT.
These mutant cDNAs were cloned into the
EcoRI/XbaI site of pcDNA3 or used as
templates to generate via the PCR a 165-bp fragment containing the N-
and C-terminal fingers of GATA4 that were subsequently cloned into the
EcoRI site of pGEX4T-3. pcDNAFlag was constructed by insertion of an oligonucleotide
(5'-AAGCTTACCATGGACTACAAAGACGATGACGACAAGGATCC) encoding the Flag
protein epitope (MDYKDDDDKD) into the
HindIII/BamHI sites of pcDNA3. FOG-2
truncations were created as follows: FOG-2-(227-1151) primers
(5'-GTGGATCCATTCAGCTGCTTCCTCAGCAAGC and 5'-TTCAGGTGCATTTCTAGAGCTCGG) and the PCR were used to generate a 257-bp fragment that was cloned into the BamHI/XbaI sites of pcDNAFlag.
Subsequently, a 3.5-kb XbaI fragment from the FOG-2 cDNA
(1208-4770 bp) was cloned into the XbaI site.
FOG-2-(534-1151) primers (5'-GTGGATCCAGCTACCCTCCTGTGATTTACAGC and
5'-TTGTGCGCCAGATAGTTCTCGACC) were used to generate a 654-bp BamHI/NotI fragment that was cloned into the
BamHI/NotI sites of pcDNAFlag. Subsequently,
a 2.2-kb NotI fragment from the FOG-2 cDNA (2526-4770
bp) was cloned into the NotI site. FOG-2-(735-1151) primers
(5'-CGGGATCCACGCAAGCGAAGAAAGATGTACG and
5'-GGCTCGAGAACACGGGTACCAAAGGTGACTGC) and the PCR were used to generate
a 1.3-kb fragment from the FOG-2 cDNA (2478-3777 bp) that was
inserted into the BamHI/XhoI site of
pcDNAFlag. FOG-2-(752-1151), a NotI fragment of the
FOG-2 cDNA (2562-4770 bp), was cloned into the NotI
site of pcDNAFlag. FOG-2-(1-733), a 2.3-kb
BamHI/FspI fragment of the FOG-2 cDNA
(132-2472 bp), was cloned into the BamHI/EcoRV
sites of pcDNA3. FOG-2-(1-506)- pcDNA FOG-2 was digested with
EcoRV to remove a 2.9-kb fragment. FOG-2-(1-312)-pcDNA
FOG-2 was digested with XbaI to remove a 3.6-kb fragment.
FOG-2-(1-247) primers (5'-GAAATTAATACGACTCACTATAGGG and
5'-GGCTCGAGTCCTTATTGACAATAGCTGTAGGC) and the PCR were used to generate
a 883-bp fragment of the FOG-2 cDNA (132-1015 bp) that was cloned into
the BamHI/XhoI sites of pcDNA3.
FOG-2-(1-312)/Gal4, FOG-2-(1-45)/Gal4, FOG-2-(46-195)/Gal4,
FOG-2-(183-240)/Gal4, and FOG-2-(241-312)/Gal4 were constructed by
cloning the appropriate fragments from the FOG-2 cDNA 3' of the GAL4
DNA binding domain in the pM vector (CLONTECH).
FOG-2-(290-668) primers (5'-GCGGATCCTAACTCGCATCAGGTTTCCAGCCTG and
5'-CCGCTCGAGAACAGGCTTTCCGTTTATTTTGTCG) and the PCR were used to
generate a 1.1-kb fragment from the FOG-2 cDNA (1140-2276 bp) that was
subsequently inserted into the BamHI/XhoI sites
of pcDNAFlag.
PcDNA3-CtBP-2 was generated by cloning a 500-bp
EcoRI/XhoI fragment encoding the 5'-end of the
murine CtBP-2 from an expressed sequence tag clone
(GenBankTM accession no. AA433525) into the
EcoRI/XhoI site of pcDNA3. Subsequently, a
XhoI/XbaI fragment containing the 3'-end of the CtBP-2 cDNA was cloned into the XhoI/XbaI site.
Transfections--
NIH 3T3 fibroblasts were transfected using 5 µg of DNA and the Superfect reagent (Qiagen, Valencia, CA) following
the manufacturer's instructions. All transfections were done in
triplicate and contained 200 ng of pVR Electrophoretic Mobility Shift Assays--
NIH 3T3 fibroblasts
were transfected with pcDNA3-GATA4, pcDNA3-FOG-2, or both;
48 h after transfection cells were harvested, and nuclear extracts
were prepared as described previously (33). The cardiac enhancer
factor-1 oligonucleotide (5'-GCCAGCCTGAGATTACAGG), which contains the
GATA4 binding site from the cTnC enhancer (20, 35), was
32P-labeled with the Klenow fragment of DNA polymerase.
This oligonucleotide was incubated in the presence of 30 µg of
nuclear extract for 20 min at 4 °C, and protein-DNA complexes were
resolved by electrophoresis in 4% nondenaturing gels and
visualized by autoradiography as described previously (16).
In Vitro Binding Assays--
In vitro binding assays
were performed as described previously (33). Briefly, DH5 Indirect Immunofluorescence--
Anti-FOG-2 antibodies were
generated by inoculating rabbits with a purified, bacterially expressed
FOG-2 GST fusion protein encoding amino acids 1-247 of the FOG-2
protein (Pocono Rabbit Farm, Canadensis, PA). COS-7 fibroblasts were
transfected with pcDNA FOG-2, pcDNA FOG-2-(227-1151),
pcDNA FOG-2-(1-733), pcDNA FOG-2-(752-1152), or pcDNA
FOG-2-(735-1152) using LipofectAMINE (Life Technologies, Inc.).
Forty-eight hours after transfection, cells were fixed in 3.7%
formaldehyde for 10 min and then permeablized using 0.2% Triton X-100
(5 min at room temperature). Subsequently, cells were blocked with 5%
fetal bovine serum for 1 h at room temperature and then incubated
with a 1:1000 dilution of anti-FOG-2 antibody or mouse monoclonal M5
anti-flag antibody (Eastman Kodak Co.) in 5% fetal bovine serum (1 h,
37 °C). Cells were washed and incubated with a 1:1000 dilution of
Cy3-conjugated goat anti-rabbit or goat anti-mouse antibody (Jackson
ImmunoResearch, West Grove, PA) for 45 min at 37 °C and then washed
five times with phosphate-buffered saline. Fluorescence was visualized
using a Zeiss Axiophot microscope.
FOG-2 Represses GATA-dependent Transcription from
Cardiac Promoters--
We have shown previously that FOG-2 is a potent
inhibitor of the GATA4-dependent transactivation of several
cardiac-restricted promoters including those from the cTnC, BNP, and
ANF genes (33). To determine if FOG-2 is capable of repressing
transcription from these promoters by other transcriptional activators,
NIH 3T3 cells were transiently transfected with expression plasmids for
GATA4, FOG-2, and Nkx2.5 and a growth hormone reporter plasmid
containing 638 bp of the rat ANF promoter that contains functionally
important binding sites for both GATA4 and Nkx2.5 (Fig.
1). Consistent with previous reports,
both GATA4 and Nkx2.5 alone transactivated the ANF promoter more than
150-fold (3, 22, 25, 36). Moreover, co-transfection of 3T3 cells with
both GATA4 and Nkx2.5 expression constructs resulted in the synergistic
activation of this promoter by more than 1100-fold. Forced expression
of FOG-2 repressed transactivation of the ANF promoter by GATA4 but had
no effect on the Nkx2.5-mediated activation of this same promoter.
Interestingly, expression of FOG-2 repressed the synergistic activation
of the ANF promoter by Nkx2.5 and GATA4, reducing the transactivation
of the ANF promoter to the level of activation seen with Nkx2.5
expression alone. These results demonstrated that FOG-2 represses
GATA4-dependent but not Nkx2.5-dependent
transcription from the ANF promoter and that this repressor function
therefore does not reflect a generalized or nonspecific inhibition of
ANF promoter activity.
Single Amino Acid Substitutions in the N-terminal Zinc Finger of
GATA4 Abolish FOG-2 Binding and Transcriptional
Repression--
Previous studies have identified naturally occurring
mutations in the N-terminal zinc finger of the Drosophila GATA protein, Pannier, that abolish its ability to interact with the FOG-2-related Drosophila protein, U-shaped (37). Similar mutations in the N-terminal
zinc finger of GATA1 have been shown to abolish its interactions with
FOG (38). To test the effects of such mutations on the GATA4-FOG-2
interaction, we used PCR-based mutagenesis to generate single amino
acid substitutions in the N-terminal zinc finger of GATA4 (D2 = Gly233
Electrophoretic mobility shift assays were used to determine if the D2
or D4 mutations had altered the DNA binding activity of GATA4. In these
experiments, NIH 3T3 fibroblasts were transfected with expression
constructs encoding wild-type or mutant GATA4. Forty-eight hours after
transfection, cells were harvested, and nuclear extracts normalized by
Western blot analysis for GATA4 levels were assayed by electrophoretic
mobility shift assay using a radiolabeled probe from the murine cTnC
enhancer cardiac enhancer factor-1. As shown in Fig. 2C,
neither the D2 nor the D4 mutation resulted in significant changes in
the DNA binding activity of GATA4. Finally, NIH 3T3 cells were
transfected with expression constructs encoding FOG-2 and either
wild-type, D2, or D4 mutant GATA4 along with a reporter plasmid
containing 1 kb of the BNP promoter-driving expression of the human
growth hormone gene. The pVR Multiple Zinc Fingers of FOG-2 Can Mediate Binding to
GATA4--
To more precisely identify the domains of FOG-2 required
for GATA4 binding and transcriptional repression, we constructed a
series of eukaryotic expression constructs containing N- and C-terminal
truncations of FOG-2 (Fig.
3A). These constructs were used to generate 35S-labeled protein for in
vitro GST binding reactions as shown in Fig. 3B.
Deletion of aa 1-534, containing zinc fingers 1-4, did not affect the
ability of FOG-2 to bind to GATA4 (Fig. 3B, lane
5). In contrast, the deletion of an additional 218 amino acids (aa
1-752) containing zinc fingers 5 and 6 resulted in a marked reduction
in GATA4 binding (Fig. 3B, lane 6). Deletion of
418 amino acids from the C terminus of FOG-2 (aa 733-1151) also did
not affect GATA4 binding (Fig. 3B, lane 7).
However, the further deletion of zinc fingers 5 and 6 resulted in
significantly decreased binding to GATA4 (Fig. 3B,
lane 8). As expected, removal of all of the zinc fingers of
FOG-2 resulted in the complete loss of GATA4 binding activity (Fig.
3B, lane 10). Interestingly, however, a peptide
containing aa 1-312 of FOG-2 and including only zinc finger 1 retained
GATA4 binding activity (Fig. 3B, lane 9) as did a
peptide containing aa 1-506 of FOG-2. The decreased binding of aa
1-506 as compared with 1-312 may have reflected differences in the
tertiary structures of these various artificial deletion constructs.
However, the binding of both aa 1-312 and 1-506 was confirmed in the
transcriptional repression assays shown in Fig. 3C (see
below). Interestingly, fusion of zinc finger 6 of FOG-2 to a peptide
containing aa 1-247 from the N terminus of the protein also restored
GATA4 binding activity (Fig. 3B, lane 11). In
contrast, a peptide containing zinc fingers 2-5 (aa 290-668) was
incapable of binding to GATA4 (Fig. 3B, lane 12).
Taken together, these results demonstrated that either zinc finger 1 or
zinc finger 6 of FOG-2 are sufficient to mediate binding to GATA4.
Identification of Functionally Conserved N-terminal Transcriptional
Repressor Domains in FOG-2 and FOG--
To better define the protein
domain(s) required for the transcriptional repressor activity of FOG-2,
we used transient transfection assays to test the ability of the N- and
C-terminal deletion mutants shown in Fig. 3A to repress
GATA4-mediated transactivation of the ANF promoter (Fig.
3C). Deletion of aa 1-226 abolished the ability of FOG-2 to
repress GATA4-dependent transcription without altering its
ability to physically interact with the N-terminal zinc finger of
GATA4. In contrast, C-terminal deletions did not significantly affect
the ability of FOG-2 to repress GATA4-dependent transcription until all of the zinc fingers were removed, resulting in
the loss of GATA4 binding activity. From these experiments, we
concluded that aa 1-226 of FOG-2 are required for its transcriptional repressor function.
Interestingly, expression of FOG-2 peptides lacking the repression
domain (aa 1-226) but containing either aa 227-1151 or aa 290-668
resulted in superactivation of GATA4-dependent
transcription (p = 0.02 and p = 0.03, respectively) as compared with the transfection lacking FOG-2 (Fig.
3C). This result suggested that these peptides that both
bind GATA4 but lack the N-terminal repressor domain might be
functioning as dominant-negative repressors (i.e.
activators) in this assay. As such, they lent further support to the
important role of aa 1-227 in the transcriptional repressor function
of FOG-2 and suggested that 3T3 cells may express an endogenous
FOG-like activity. This possibility is currently under investigation.
Previous studies have demonstrated that FOG is a potent repressor of
GATA1-dependent transcription in transient transfection assays (27, 29). Although the zinc fingers of FOG and FOG-2 are highly
conserved, the N-terminal domains of the two proteins are only 27%
identical at the amino acid level (Fig.
4A). Thus, it was of interest
to determine 1) if FOG, like FOG-2, could repress the
GATA4-dependent activation of cardiac promoters and 2) if so, whether the N-terminal domain of FOG was also required for its
transcriptional repressor activity. As shown in Fig. 4B,
full-length FOG repressed the GATA4-mediated activation of the ANF
promoter in 3T3 cells. Moreover, deletion of the N-terminal domain of
FOG (aa 1-230) abolished this transcriptional repression. Taken
together, these results identified a functionally conserved N-terminal
transcriptional repression domain in both known mammalian FOG
proteins.
Several experiments were performed to determine if the N-terminal
repressor domain of FOG-2 was also sufficient to mediate repression of
GATA4-dependent transcription. First, fusion of zinc finger
6 of FOG-2 to the N-terminal aa 1-247 was shown to simultaneously
restore GATA4 binding and transcriptional repressor activity (Fig.
3C; aa 1-247 and 668-724). Similarly, the addition of zinc
finger 1 to the N-terminal 247 amino acids also restored both GATA4
binding and transcriptional repression (Fig. 3C, aa 1-312).
Finally, we fused the heterologous DNA binding domain of Gal4 to the
putative transcriptional repression domain of FOG-2 (aa 1-312) and
assayed the ability of this fusion protein to inhibit transcription
from an SV40 promoter juxtaposed to four Gal4 DNA binding sites in the
pSV40Gal4luciferase reporter plasmid. As shown in Fig.
5, the Gal4·FOG-2-(1-312) fusion
protein was a potent inhibitor of SV40-dependent
transcription. We further mapped this repression domain by fusing
shorter fragments from this region of FOG-2 to the Gal4 DNA binding
domain. As shown in Fig. 5, amino acids 1-45 of FOG-2 were sufficient
to repress SV40-dependent transcription when fused to the
Gal4 DNA binding domain. This effect was specific for this FOG-2
peptide because in control experiments expression of the Gal4 DNA
binding domain alone or Gal4 fusion proteins containing aa 46-195,
183-240, or 241-312 of FOG-2 failed to repress
SV40-dependent transcription (Fig. 5). Taken together,
these experiments demonstrated that aa 1-247 of FOG-2 are both
necessary and sufficient to repress GATA4- (and SV40-) dependent
transcription so long as they are tethered to a domain that can bring
this peptide into contiguity with the promoter/enhancer on the DNA.
Mapping of a Nuclear Localization Signal in FOG-2--
We have
shown previously that FOG-2 is localized in the nucleus of both primary
rat neonatal cardiomyocytes and COS-7 cells transfected with a FOG-2
expression construct (33). To ensure that the loss of FOG-2 repressor
activity observed following deletion of the N-terminal 247 amino acids
did not simply reflect a defect in the nuclear localization of the
mutant protein, we used the deletion mutants shown in Fig.
4A to map the putative nuclear localization signals of
FOG-2. An examination of the amino acid sequence of FOG-2 revealed a
potential nuclear localization signal (RKRRK) at aa 736-740. To
determine the importance of this site for the subcellular localization
of FOG-2, we transfected COS-7 fibroblasts with the N- and C-terminal
truncation mutants of FOG-2 described in Fig. 3A. Indirect
immunofluorescence was used to determine the subcellular localization
of these truncation mutants with representative data shown in Fig.
6. Both full-length FOG-2 and N-terminal
truncations containing aa 736-740 were localized exclusively to the
nucleus. Thus, the loss of repressor function by N-terminal truncations
lacking aa 1-247 was not because of the loss of nuclear localization.
In contrast, removal of aa 736-740 resulted in redistribution of the
resultant proteins to both the cytoplasm and the nucleus (Fig. 6,
compare aa 735-1151 and aa 752-1151). Similarly, all C-terminal
truncations lacking aa 736-740 were localized to both the nucleus and
cytoplasm. However, each of these C-terminal deletion mutants repressed
GATA4-dependent transcription (Fig. 3C). Thus,
we concluded that the nuclear localization signal located between aa
736 and 740 is required for exclusive nuclear localization of FOG-2 and
that the inability of the FOG-2 N-terminal truncations to repress GATA4
transactivation was not because of disrupted nuclear localization.
The Transcriptional Repressor CtBP-2 Binds to FOG-2 but Is Not
Required for FOG-2-mediated Repression of GATA4-dependent
Transcription--
One mechanism by which FOG-2 might inhibit
GATA4-dependent transcription is by recruiting one or more
transcriptional co-repressors to the GATA4·FOG-2 complex. One such
co-repressor is CtBP-2, which has been shown previously to bind to FOG
via a consensus CtBP binding site (PIDLS) (29, 31). This putative CtBP
binding site is also present in FOG-2 (aa 830-834). The ability of
FOG-2 to bind CtBP-2 was tested using GST binding assays (Fig.
7B). GST·CtBP-2 specifically
bound to full-length in vitro translated FOG-2 and to an
N-terminal deletion of FOG-2 (aa 227-1151) that contains the PIDLS
sequence but failed to bind to a C-terminal truncation (aa 1-733) that
lacks this site. Thus, FOG-2, like FOG, is capable of binding
CtBP-2.
To test the functional significance of the FOG-2-CtBP-2 interaction,
NIH 3T3 fibroblasts were transfected with expression constructs
encoding full-length or truncated FOG-2, CtBP-2, GATA4, and an ANF
promoter reporter construct. Full-length FOG-2 repressed GATA4-dependent transcription from the ANF promoter by
7-fold (Fig. 7C). In contrast, expression of CtBP-2
repressed GATA4-mediated activation of the ANF promoter by only 20%.
This modest repression by CtBP-2 occurred both in the presence and
absence of FOG-2 indicating that it was not
FOG-2-dependent. More importantly, deletion of the CtBP-2
binding site in FOG-2-(1-733), which abolished CtBP-2 binding (Fig.
7B), did not decrease the transcriptional repressor activity
of FOG-2 (Fig. 7C; compare wild-type FOG-2 and
FOG-2-(1-773)). From these experiments, we concluded that, at least in
this experimental system, CtBP-2 is neither sufficient nor necessary
for the transcriptional repressor function of FOG-2.
FOG-2 is a member of a family of evolutionarily conserved
multizinc finger transcriptional modulators that includes the
Drosophila protein, U-shaped, and the mammalian protein, FOG (26, 29, 30, 32-34). Each of the FOG proteins is known to interact with one or
more GATA factors and to thereby co-activate or repress their
transcriptional activities. Previous studies have demonstrated that
FOG-2 is co-expressed with GATA4 in both embryonic and adult cardiomyocytes, can bind specifically to the N-terminal zinc finger of
GATA4, and can function as a potent repressor of
GATA4-dependent transcription in both fibroblasts and
cardiomyocytes (29, 32-34). However, relatively little was previously
understood about the molecular basis of the GATA4-FOG-2 interaction and
the transcriptional repressor activity of FOG-2.
In the studies described in this report, we have investigated the
mechanisms underlying FOG-2-mediated transcriptional repression of
cardiac-restricted promoters. The results have identified
evolutionarily conserved modules within the FOG proteins that mediate
their specific interactions with GATA transcription factors, program
their nuclear localization, and determine their transcriptional
repressor activities. Specifically, we have shown that 1) zinc fingers
1 and 6 are each capable of interacting with evolutionarily conserved
motifs within the N-terminal zinc finger of all of the mammalian GATA
proteins, 2) a structurally conserved binding site in FOG-2 (PIDLS) is
required for the its interaction with CtBP-2, and 3) a nuclear
localization signal (RKRRK) between aa 736 and 740 of FOG-2 is required
to program the exclusive nuclear targeting of the protein. Finally, and
most importantly we have identified novel and functionally conserved
domains at the N termini of FOG and FOG-2 that are both necessary and
sufficient to repress GATA4-dependent transcriptional activation. Moreover, we have shown that this repression is independent of the transcriptional co-repressor CtBP-2. Taken together, these findings begin to define a set of evolutionarily conserved mechanisms by which FOG proteins repress GATA-dependent transcription
in multiple cell lineages. As such, they have important implications for understanding the mechanism(s) by which FOG-2 modulates
GATA4-dependent transcription in cardiomyocytes.
Previous studies suggested that the transcriptional repressor activity
of FOG proteins is mediated by the binding of the transcriptional co-repressor CtBP-2 (29). In contrast, our results demonstrate that
CtBP-2 binding by FOG-2 is neither necessary nor sufficient for the
FOG-2-mediated repression of GATA4-dependent transcription. Instead, we have identified novel and functionally conserved repressor domains at the N termini of both FOG and FOG-2 that are necessary and
sufficient for repressing the GATA-dependent activation of cardiac-restricted promoters. Our finding of CtBP-2-independent transcriptional repression by FOG proteins is supported by in vitro mutagenesis studies showing that CtBP-2 binding is also not
necessary for the FOG-mediated repression of
GATA1-dependent transcription. Mutation of the CtBP-2
binding site in FOG resulted in only a 2-fold reduction in FOG-mediated
repression of GATA1-dependent transcription. Thus, although
both FOG and FOG-2 contain conserved and functional CtBP-2 binding
sites, binding to CtBP-2 is not required for the ability of these
proteins to repress either GATA1 or GATA4-dependent
transcription. However, it should be emphasized that it remains
possible that CtBP-2 enhances the transcriptional repressor activity of
FOG-2 for GATA4 on some promoters in vivo. In this regard it
will be of interest to mutate the CtBP-2 binding site of FOG-2 in mice
and to compare their phenotype to that of the FOG-2 knockout mice that
have recently been produced in our laboratory.2
The finding that the N terminus of FOG-2 is both necessary and
sufficient for repression of GATA4-dependent transcription and that this domain can repress transcription even when fused to the
Gal4 DNA binding domain is consistent with a model in which the
N-terminal region of FOG-2 either binds one or more co-repressors or
interferes with the activity of transcriptional co-activators or basal
transcription factors. The N-terminal repression domains of FOG and
FOG-2 display only 27% sequence identity (Fig. 4A). However, these two peptides share several structural motifs. The N-terminal domains of both peptides are acidic and proline-rich. In
addition, several regions of the peptides (e.g. aa 1-24 and 102-136) display significant sequence identity (Fig. 4A).
These structurally similar motifs might represent shared binding
domains for nuclear modulators of GATA-dependent
transcription. Ongoing yeast two-hybrid studies designed to identify
specific binding partners for the FOG repressor domains should allow us
to distinguish these possibilities and to identify additional proteins
that help to mediate the repressor activity of FOG-2.
The fact that a single amino acid substitution (Glu215 In summary, the FOG-GATA interaction has been evolutionarily conserved
from flies to man. The physiologic significance of this interaction is
underscored by the evolutionary conservation of the two families of
proteins and by the fact that in all cases studied to date, FOG and
GATA family members are co-expressed in the same cell lineages. Taken
together with previous results, our studies demonstrate that a
conserved set of structural motifs in both proteins determine their
interactions and regulate the FOG-mediated repression of
GATA-dependent transcription. A complete understanding of
the physiological function of FOG-2 will await the phenotype of the
FOG-2 knockout mice and the identification and better understanding of
proteins that interact with FOG-2. By defining the functionally
important domains of FOG-2, the results described in this report form
the foundation for these ongoing studies of FOG-2-regulated cardiac
gene expression.
We acknowledge R. Doherty for help in
preparing this manuscript, T. Lis for help with the preparation of
illustrations, and C. Bacani for technical assistance.
*
This work was supported in part by Grant HL54592 from the
NHLBI, National Institutes of Health (to J. M. L.).The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
¶
To whom correspondence should be addressed: Harvard School of
Public Health, Bldg. II, Rm. 117, 677 Huntington Ave., Boston, MA
02115. Tel.: 617-432-3444; Fax: 617-432-3794; E-mail:
leiden@cvlab. harvard.edu.
Published, JBC Papers in Press, May 2, 2000, DOI 10.1074/jbc.M001522200
2
E. Svensson, G. Huggins, and J. Leiden,
unpublished data.
The abbreviations used are:
FOG, Friend of
GATA1;
CtBP2, C-terminal-binding protein-2;
aa, amino acids;
PCR, polymerase chain reaction;
bp, base pair(s);
kb, kilobase(s);
GST, glutathione S-transferase;
cTnC, cardiac troponin C;
ANF, atrial natriuretic factor;
BNP, brain natriuretic peptide.
A Functionally Conserved N-terminal Domain of the Friend of
GATA-2 (FOG-2) Protein Represses GATA4-Dependent Transcription*
,
,
, and
Department of Medicine, University of
Chicago, Chicago, Illinois 60637 and § The Laboratory of
Cardiovascular Biology, Harvard School of Public Health and Harvard
Medical School, Boston, Massachusetts 02115
![]()
ABSTRACT
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
![]()
MATERIALS AND METHODS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
-gal, a reference plasmid
containing the cytomegalovirus promoter driving expression of the
LacZ gene (33). Cells and medium were harvested 48 h
later and assayed for growth hormone or luciferase levels,
-galactosidase activity, and total protein content using
commercially available kits (Nichols Institute, San Juan Capistrano,
CA; Promega, Madison, WI; and Bio-Rad). Growth hormone and luciferase
levels were normalized to
-galactosidase activity and total protein
content to correct for variations in transfection and cell harvesting efficiencies.
bacteria
were transformed with DNA expression constructs encoding GST·GATA4 or
GST·mCtBP-2 fusion proteins. Bacteria were grown to mid log-phase
and induced with 1 mM
isopropyl-1-thio-
-D-galactopyranoside for 4 h at
30 °C. Bacteria were sonicated, and the resulting lysates were
incubated with 30 µl of a 50% slurry of glutathione-Sepharose for
1 h at 4 °C. Subsequently, the beads were washed four times with binding buffer (150 mM NaCl, 50 mM Tris,
pH 7.5, 0.1% Nonidet P-40, 10 µM ZnSO4,
-mercaptoethanol, 0.25% bovine serum albumin, and protease
inhibitors), and 5-15 µl of radiolabeled in vitro translated full-length or truncated FOG-2 proteins were added in a
total volume of 700 µl of binding buffer. After a 1-h incubation at
4 °C, the beads were again washed five times, and the bound proteins
were resolved by SDS-polyacrylamide gel electrophoresis and visualized
by autoradiography.
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

View larger version (16K):
[in a new window]
Fig. 1.
FOG-2 is a specific repressor of GATA4
transactivation. NIH 3T3 fibroblasts were transfected with a
reporter construct containing the human growth hormone gene under
control of the 638-bp ANF promoter and expression constructs encoding
GATA4, FOG-2, or Nkx2.5 as indicated. Forty-eight hours after
transfection, medium was assayed for human growth hormone, and the
results were normalized for differences in transfection efficiencies as
described under "Materials and Methods." Results are displayed as
the mean ± S.E. (n = 3).
Glu and D4 = Glu215
Lys)
(Fig. 2A). Both mutants
demonstrated decreased binding to FOG-2 in GST binding assays (Fig.
2B). The D2 mutation reduced FOG-2 binding by 63 ± 9%, whereas the D4 mutation reduced FOG-2 binding by 95 ± 3%.

View larger version (33K):
[in a new window]
Fig. 2.
Single amino acid substitutions in the
N-terminal zinc finger of GATA4 abrogate FOG-2-mediated transcriptional
repression. A, schematic illustration of the GATA4
N-terminal zinc finger showing the four cysteines of the zinc finger
coordinated to a zinc atom. The two amino acids altered by PCR-mediated
mutagenesis (D2, Gly233
Glu and D4, Glu215
Lys) are shaded. B, GATA4 point mutations
disrupt FOG-2 binding. In vitro binding assay using
35S-labeled, in vitro translated FOG-2 and
bacterially expressed GST, GST·WT GATA4, GST·D2 GATA4, or GST·D4
GATA4 fusion proteins. C, GATA4 point mutations do not
affect GATA4 DNA binding. Nuclear extracts prepared from NIH 3T3 cells
transfected with expression plasmids encoding wild-type (WT)
GATA4, D2 GATA4, or D4 GATA4 proteins were assayed by electrophoretic
mobility shift assay with a 32P-labeled oligonucleotide
containing the cardiac enhancer factor-1 (CEF-1) GATA4
binding site from the proximal cTnC enhancer. D, GATA4
mutations attenuate FOG-2-mediated transcriptional repression. NIH 3T3
cells were transfected with a reporter construct containing the human
growth hormone gene under the control of a 638-bp ANF promoter and
expression constructs encoding FOG-2, GATA4, D2 GATA4, or D4 GATA4.
Forty-eight hours after transfection, medium was assayed for human
growth hormone, and the results were normalized for differences in
transfection efficiencies. Results are displayed as the mean ± S.E. (n = 3).
gal reference plasmid was included in
all transfections to normalize for differences in transfection
efficiencies. As shown in Fig. 2D, both the D2 and D4
mutants were able to transactivate the BNP promoter to the same level
as wild-type GATA4. Consistent with previous work (33), FOG-2 repressed
the ability of wild-type GATA4 to activate this promoter by ~10-fold.
In contrast, activation of the BNP promoter by the D2 mutant, which
displays moderately reduced FOG-2 binding, was only repressed 3-fold by
overexpression of FOG-2. Transactivation by the D4 mutant, which fails
to interact with FOG-2, was unaffected by FOG-2. These results
suggested that the ability of FOG-2 to repress GATA4-mediated
transcriptional activation is proportional to its ability to physically
interact with the N-terminal zinc finger of GATA4. Moreover, they
demonstrated that the susceptibility of GATA4 to
FOG-2-dependent repression can be distinguished
structurally from its DNA binding and transcriptional activation functions.

View larger version (27K):
[in a new window]
Fig. 3.
Mapping of the GATA4 binding and
transcriptional repression domains of FOG-2. A,
schematic illustration of the FOG-2 primary structure showing eight
zinc finger motifs. The FOG-2 truncation mutants used in B
and C are shown schematically below the full-length FOG-2
protein. Numbers shown to the left indicate the
amino acids of FOG-2 included in each truncation. B,
multiple zinc fingers of FOG-2 can mediate the FOG-2-GATA4 interaction.
In vitro binding assays using GST or GST·GATA4 fusion
proteins and 35S-labeled in vitro translated
FOG-2 or FOG-2 truncations. C, the N-terminal domain of
FOG-2 is necessary for repression of GATA4 transactivation. NIH 3T3
fibroblasts were transfected with a reporter construct containing the
human growth hormone gene under the control of a 638-bp ANF promoter,
an expression construct encoding GATA4, and expression constructs
encoding either FOG-2 or FOG-2 truncations as indicated. Forty-eight
hours after transfection medium was assayed for human growth hormone,
and the results were normalized for differences in transfection
efficiencies. Results are displayed as the mean ± S.E.
(n = 3).

View larger version (28K):
[in a new window]
Fig. 4.
Functional conservation of an
N-terminal transcriptional repression domain in FOG. A,
comparison of the amino acid sequences of the N-terminal
transcriptional repression domains of FOG and FOG-2. Identical amino
acids are shown in the middle line between the FOG and FOG-2
sequences.
, deletion; +, conserved amino acid residues. Amino acid
numbers of FOG are shown to the right of the sequence.
B, a transcriptional repression domain in the N terminus of
FOG represses GATA4-dependent activation of the ANF
promoter. NIH 3T3 fibroblasts were transfected with a reporter
construct containing the 638-bp ANF promoter-driving human growth
hormone expression and expression constructs encoding GATA4,
full-length FOG, or a deletion mutant of FOG lacking aa 1-230
(FOG-(230-995)). Forty-eight hours after transfection, media were
assayed for human growth hormone and normalized for differences in
transfection efficiencies. Results are displayed as the mean ± S.E. (n = 3).

View larger version (19K):
[in a new window]
Fig. 5.
The N-terminal transcriptional repression
domain of FOG-2 is sufficient to mediate repression of
SV40-dependent transcription. Peptides from the
N-terminal domain of FOG-2 were fused to the Gal4 DNA binding domain in
pM. NIH 3T3 fibroblasts were transfected with the SV40Gal4luciferase
reporter construct containing four copies of the Gal4 upstream
activating sequence 5' of the SV40 promoter/enhancer and the luciferase
reporter gene in conjunction with expression vectors encoding the Gal4
DNA binding domain alone (Gal4) or the five Gal4·FOG-2 fusion
peptides (1-312, 1-45, 46-195, 183-240, and 241-312). Forty-eight
hours after transfection, cell lysates were assayed for luciferase
activity and normalized for differences in transfection efficiencies.
Results are displayed as the mean ± S.E. (n = 12). *, p = 0.001; **, p = 0.008.

View larger version (15K):
[in a new window]
Fig. 6.
Mapping of the nuclear localization signal of
FOG-2. The left panel shows a schematic illustration of
the FOG-2 protein including the sequence of the putative nuclear
localization signal (aa 745-750). The FOG-2 truncations that span the
nuclear localization signal are shown schematically below the diagram
of the full-length protein. The right panel shows indirect
immunofluorescence assays of COS-7 cells transfected with the
corresponding FOG-2 expression constructs.

View larger version (21K):
[in a new window]
Fig. 7.
CtBP-2 binds specifically to FOG-2 but is not
required for FOG-2-mediated transcriptional repressor activity.
A, schematic illustration of the truncation mutants of FOG-2
used in the CtBP-2 binding experiments. The consensus CtBP-2 binding
site (PIDLS) located between zinc fingers 6 and 7 is shown.
B, CtBP-2 binds FOG-2. In vitro binding assays
using GST or GST·CtBP-2 fusion proteins and 35S-labeled,
in vitro translated FOG-2 or FOG-2 truncations.
C, CtBP-2 does not potentiate FOG-2-mediated transcriptional
repression. NIH 3T3 cells were transfected with a reporter construct
containing the 638-bp ANF promoter driving human growth hormone
expression and an expression construct encoding GATA4. In addition,
cells were co-transfected with expression constructs encoding
full-length FOG-2, truncated FOG-2, and CtBP-2 as indicated.
Forty-eight hours after transfection, media were assayed for human
growth hormone and normalized for differences in transfection
efficiencies. Results are displayed as the mean ± S.E.
(n = 3).
![]()
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
Lys) in the N-terminal zinc finger of GATA4 can disrupt FOG-2 binding and repression without affecting the DNA binding or transcriptional activation functions of GATA4 suggests the possibility of genetically determining the function of the GATA4-FOG-2 interaction by knocking the
Lys215 mutant of GATA4 into the GATA4 locus in mice. By
comparing the phenotype of such mutant mice to those of the GATA4 and
FOG-2 knockouts that have recently been produced in our laboratory
(18),2 it should be possible to understand the
GATA4-dependent and GATA4-independent functions of FOG-2 in
the heart.
![]()
ACKNOWLEDGEMENTS
![]()
FOOTNOTES
![]()
ABBREVIATIONS
![]()
REFERENCES
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
1.
Arceci, R. J.,
King, A. A.,
Simon, M. C.,
Orkin, S. H.,
and Wilson, D. B.
(1993)
Mol. Cell. Biol.
13,
2235-2246
2.
Dorfman, D. M.,
Wilson, D. B.,
Bruns, G. A.,
and Orkin, S. H.
(1992)
J. Biol. Chem.
267,
1279-1285
3.
Durocher, D.,
Charron, F.,
Warren, R.,
Schwartz, R. J.,
and Nemer, M.
(1997)
EMBO J.
16,
5687-5696
4.
Evans, T.,
Reitman, M.,
and Felsenfeld, G.
(1988)
Proc. Natl. Acad. Sci. U. S. A.
85,
5976-5980
5.
Grepin, C.,
Dagnino, L.,
Robitaille, L.,
Haberstroh, L.,
Antakly, T.,
and Nemer, M.
(1994)
Mol. Cell. Biol.
14,
3115-3129
6.
Ho, I. C.,
Vorhees, P.,
Marin, N.,
Oakley, B. K.,
Tsai, S. F.,
Orkin, S. H.,
and Leiden, J. M.
(1991)
EMBO J.
10,
1187-1192
7.
Tsai, S. F.,
Martin, D. I.,
Zon, L. I.,
D'Andrea, A. D.,
Wong, G. G.,
and Orkin, S. H.
(1989)
Nature
339,
446-451
8.
Pevny, L.,
Simon, M. C.,
Robertson, E.,
Klein, W. H.,
Tsai, S. F.,
D'Agati, V.,
Orkin, S. H.,
and Costantini, F.
(1991)
Nature
349,
257-260
9.
Ting, C. N.,
Olson, M. C.,
Barton, K. P.,
and Leiden, J. M.
(1996)
Nature
384,
474-478
10.
Tsai, F. Y.,
Keller, G.,
Kuo, F. C.,
Weiss, M.,
Chen, J.,
Rosenblatt, M.,
Alt, F. W.,
and Orkin, S. H.
(1994)
Nature
371,
221-226
11.
Laverriere, A. C.,
MacNeill, C.,
Mueller, C.,
Poelmann, R. E.,
Burch, J. B.,
and Evans, T.
(1994)
J. Biol. Chem.
269,
23177-23184
12.
Morrisey, E. E.,
Ip, H. S.,
Lu, M. M.,
and Parmacek, M. S.
(1996)
Dev. Biol.
177,
309-322
13.
Morrisey, E. E.,
Ip, H. S.,
Tang, Z.,
Lu, M. M.,
and Parmacek, M. S.
(1997)
Dev. Biol.
183,
21-36
14.
Wilson, D. B.,
Dorfman, D. M.,
and Orkin, S. H.
(1990)
Mol. Cell. Biol.
10,
4854-4862
15.
Huang, W. Y.,
Cukerman, E.,
and Liew, C. C.
(1995)
Gene (Amst.)
155,
219-223
16.
Ip, H. S.,
Wilson, D. B.,
Heikinheimo, M.,
Tang, Z.,
Ting, C. N.,
Simon, M. C.,
Leiden, J. M.,
and Parmacek, M. S.
(1994)
Mol. Cell. Biol.
14,
7517-26
17.
Molkentin, J. D.,
Kalvakolanu, D. V.,
and Markham, B. E.
(1994)
Mol. Cell. Biol.
14,
4947-4957
18.
Kuo, C. T.,
Morrisey, E. E.,
Anandappa, R.,
Sigrist, K.,
Lu, M. M.,
Parmacek, M. S.,
Soudais, C.,
and Leiden, J. M.
(1997)
Genes Dev.
11,
1048-1060
19.
Molkentin, J. D.,
Lin, Q.,
Duncan, S. A.,
and Olson, E. N.
(1997)
Genes Dev.
11,
1061-1072
20.
Ko, L. J.,
and Engel, J. D.
(1993)
Mol. Cell. Biol.
13,
4011-4022
21.
Merika, M.,
and Orkin, S. H.
(1993)
Mol. Cell. Biol.
13,
3999-4010
22.
Lee, Y.,
Shioi, T.,
Kasahara, H.,
Jobe, S. M.,
Wiese, R. J.,
Markham, B. E.,
and Izumo, S.
(1998)
Mol. Cell. Biol.
18,
3120-3129
23.
Merika, M.,
and Orkin, S. H.
(1995)
Mol. Cell. Biol.
15,
2437-2447
24.
Molkentin, J. D.,
Lu, J. R.,
Antos, C. L.,
Markham, B.,
Richardson, J.,
Robbins, J.,
Grant, S. R.,
and Olson, E. N.
(1998)
Cell
93,
215-228
25.
Sepulveda, J. L.,
Belaguli, N.,
Nigam, V.,
Chen, C. Y.,
Nemer, M.,
and Schwartz, R. J.
(1998)
Mol. Cell. Biol.
18,
3405-3415
26.
Cubadda, Y.,
Heitzler, P.,
Ray, R. P.,
Bourouis, M.,
Ramain, P.,
Gelbart, W.,
Simpson, P.,
and Haenlin, M.
(1997)
Genes Dev.
11,
3083-3095
27.
Fox, A. H.,
Kowalski, K.,
King, G. F.,
Mackay, J. P.,
and Crossley, M.
(1998)
J. Biol. Chem.
273,
33595-33603
28.
Fox, A. H.,
Liew, C.,
Holmes, M.,
Kowalski, K.,
Mackay, J.,
and Crossley, M.
(1999)
EMBO J.
18,
2812-2822
29.
Holmes, M.,
Turner, J.,
Fox, A.,
Chisholm, O.,
Crossley, M.,
and Chong, B.
(1999)
J. Biol. Chem.
274,
23491-23498
30.
Tsang, A. P.,
Visvader, J. E.,
Turner, C. A.,
Fujiwara, Y., Yu, C.,
Weiss, M. J.,
Crossley, M.,
and Orkin, S. H.
(1997)
Cell
90,
109-119
31.
Turner, J.,
and Crossley, M.
(1998)
EMBO J.
17,
5129-5140
32.
Lu, J. R.,
McKinsey, T. A.,
Xu, H.,
Wang, D. Z.,
Richardson, J. A.,
and Olson, E. N.
(1999)
Mol. Cell. Biol.
19,
4495-4502
33.
Svensson, E. C.,
Tufts, R. L.,
Polk, C. E.,
and Leiden, J. M.
(1999)
Proc. Natl. Acad. Sci. U. S. A.
96,
956-961
34.
Tevosian, S. G.,
Deconinck, A. E.,
Cantor, A. B.,
Rieff, H. I.,
Fujiwara, Y.,
Corfas, G.,
and Orkin, S. H.
(1999)
Proc. Natl. Acad. Sci. U. S. A.
96,
950-955
35.
Parmacek, M. S.,
Vora, A. J.,
Shen, T.,
Barr, E.,
Jung, F.,
and Leiden, J. M.
(1992)
Mol. Cell. Biol.
12,
1967-1976
36.
Shiojima, I.,
Komuro, I.,
Oka, T.,
Hiroi, Y.,
Mizuno, T.,
Takimoto, E.,
Monzen, K.,
Aikawa, R.,
Akazawa, H.,
Yamazaki, T.,
Kudoh, S.,
and Yazaki, Y.
(1999)
J. Biol. Chem.
274,
8231-8239
37.
Haenlin, M.,
Cubadda, Y.,
Blondeau, F.,
Heitzler, P.,
Lutz, Y.,
Simpson, P.,
and Ramain, P.
(1997)
Genes Dev.
11,
3096-3108
38.
Crispino, J. D.,
Lodish, M. B.,
MacKay, J. P.,
and Orkin, S. H.
(1999)
Mol. Cell
3,
219-228
Copyright © 2000 by The American Society for Biochemistry and Molecular Biology, Inc.
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
![]() |
R. K. Bruton, P. Pelka, K. L. Mapp, G. J. Fonseca, J. Torchia, A. S. Turnell, J. S. Mymryk, and R. J. A. Grand Identification of a Second CtBP Binding Site in Adenovirus Type 5 E1A Conserved Region 3 J. Virol., September 1, 2008; 82(17): 8476 - 8486. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. S. Viger, S. M. Guittot, M. Anttonen, D. B. Wilson, and M. Heikinheimo Role of the GATA Family of Transcription Factors in Endocrine Development, Function, and Disease Mol. Endocrinol., April 1, 2008; 22(4): 781 - 798. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. D. Clugston, W. Zhang, and J. J. Greer Gene expression in the developing diaphragm: significance for congenital diaphragmatic hernia Am J Physiol Lung Cell Mol Physiol, April 1, 2008; 294(4): L665 - L675. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. M. Lauberth and M. Rauchman A Conserved 12-Amino Acid Motif in Sall1 Recruits the Nucleosome Remodeling and Deacetylase Corepressor Complex J. Biol. Chem., August 18, 2006; 281(33): 23922 - 23931. [Abstract] [Full Text] [PDF] |
||||
![]() |
M Anttonen, H Parviainen, A Kyronlahti, M Bielinska, D B Wilson, O Ritvos, and M Heikinheimo GATA-4 is a granulosa cell factor employed in inhibin-{alpha} activation by the TGF-{beta} pathway. J. Mol. Endocrinol., June 1, 2006; 36(3): 557 - 568. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Rath, Z. Wang, M. M. Lu, and E. E. Morrisey LMCD1/Dyxin Is a Novel Transcriptional Cofactor That Restricts GATA6 Function by Inhibiting DNA Binding Mol. Cell. Biol., October 15, 2005; 25(20): 8864 - 8873. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. C. Lin, A. E. Roche, J. Wilk, and E. C. Svensson The N Termini of Friend of GATA (FOG) Proteins Define a Novel Transcriptional Repression Motif and a Superfamily of Transcriptional Repressors J. Biol. Chem., December 31, 2004; 279(53): 55017 - 55023. [Abstract] [Full Text] [PDF] |
||||
![]() |
T.-g. Kim, J. Chen, J. Sadoshima, and Y. Lee Jumonji Represses Atrial Natriuretic Factor Gene Expression by Inhibiting Transcriptional Activities of Cardiac Transcription Factors Mol. Cell. Biol., December 1, 2004; 24(23): 10151 - 10160. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Hirai, K. Ono, T. Morimoto, T. Kawamura, H. Wada, T. Kita, and K. Hasegawa FOG-2 Competes with GATA-4 for Transcriptional Coactivator p300 and Represses Hypertrophic Responses in Cardiac Myocytes J. Biol. Chem., September 3, 2004; 279(36): 37640 - 37650. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Pikkarainen, H. Tokola, R. Kerkela, and H. Ruskoaho GATA transcription factors in the developing and adult heart Cardiovasc Res, August 1, 2004; 63(2): 196 - 207. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. M. Barrett, K. S. Gustafson, J. Wang, S. Z. Wang, and G. D. Ginder A GATA Factor Mediates Cell Type-Restricted Induction of HLA-E Gene Transcription by Gamma Interferon Mol. Cell. Biol., July 15, 2004; 24(14): 6194 - 6204. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. J. Hatcher, N. Y.S.-G. Diman, M.-S. K |